Connective Tissue Diseases clinical trials at UCLA
3 in progress, 0 open to eligible people
Ralinepag to Improve Treatment Outcomes in PAH Patients
Sorry, in progress, not accepting new patients
Study ROR-PH-301, ADVANCE OUTCOMES, is designed to assess the efficacy and safety of ralinepag when added to pulmonary arterial hypertension (PAH) standard of care or PAH-specific background therapy in subjects with World Health Organization (WHO) Group 1 PAH.
Los Angeles 5368361, California 5332921 and other locations
Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension
Sorry, accepting new patients by invitation only
Study ROR-PH-303, ADVANCE EXTENSION, is an open-label extension (OLE) study for participants with WHO Group 1 PAH who have participated in another Phase 2 or Phase 3 study of ralinepag.
Los Angeles 5368361, California 5332921 and other locations
Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension
Sorry, in progress, not accepting new patients
The purpose of this phase 2 multicenter, randomized, double-blind, placebo-controlled, study is to assess the safety and efficacy of ifetroban in patients with diffuse cutaneous systemic SSc (dcSSc) or SSc-associated pulmonary arterial hypertension (SSc-PAH).
Los Angeles 5368361, California 5332921 and other locations
Last updated: